Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Collegium Pharmaceutical, Inc. (COLL) vs Ironwood Pharmaceuticals, Inc. (IRWD)

Collegium Pharmaceutical, Inc. and Ironwood Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Collegium Pharmaceutical, Inc. and Ironwood Pharmaceuticals, Inc. are of similar size ($737.1M and $692.4M). Ironwood Pharmaceuticals, Inc. trades at the lower P/E: 5.2× against 14.7×. Ironwood Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 26.2% against 14.3%. Ironwood Pharmaceuticals, Inc. has the higher net margin (33.4% vs 5.93%) and the higher return on invested capital (101.6% vs 7.85%). Across the 20 metrics below, Ironwood Pharmaceuticals, Inc. leads on 13 and Collegium Pharmaceutical, Inc. on 7.

Valuation

Metric COLL IRWD Drug Manufacturers Specialty & Generic median
P/E 14.73 5.18 20.14
P/S 0.90 1.74 2.25
P/B 2.34 n/m 1.90
Price to free cash flow n/m 3.66 16.54
EV/EBITDA 4.29 5.02 12.29
EV/Sales 2.07 3.04 2.56
Earnings yield 6.79% 19.31% (2.99%)
Free cash flow yield (5.46%) 27.32% 0.00%

Profitability

Metric COLL IRWD Drug Manufacturers Specialty & Generic median
Gross margin 60.02% 100.00% 53.94%
Operating margin 19.48% 60.15% 0.00%
Net margin 5.93% 33.36% 0.00%
Free cash flow margin 40.62% 47.66% 0.00%
Return on equity 17.61% (55.26%) (0.40%)
Return on assets 2.57% 41.35% (3.32%)
Return on invested capital 7.85% 101.61% 0.00%

Growth

Metric COLL IRWD Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 14.31% 26.19% 10.01%
EPS growth (last fiscal year) (6.99%) 2,627.27% —
Revenue growth, 5-year CAGR 20.28% (5.33%) 6.74%
Net income growth, 5-year CAGR 18.64% (25.72%) 0.00%

Health

Metric COLL IRWD Drug Manufacturers Specialty & Generic median
Debt to equity 3.50 (2.38) 0.05
Current ratio 1.03 6.06 2.31
Net debt to EBITDA 1.00 3.68 0.85

Dividend

Metric COLL IRWD Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric COLL IRWD Drug Manufacturers Specialty & Generic median
Market cap 737.06m 692.36m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack